جست‌وجوی استاد و پژوهشگر

• Iron Homeostasis
• Cell Physiology
• Systems Biology
• +۴ مورد دیگر

Dr. Samira Lakhal-Littleton is an Associate Professor of Cell Physiology and MRC Senior Non-Clinical Research Fellow at the University of Oxford, affiliated with the Department of Physiology, Anatomy and Genetics and Brasenose College. Her research focuses on iron homeostasis, systems biology, and oxygen sensing mechanisms in cardiovascular and systemic physiology. Education: BSc in Human Genetics (University College London), DPhil in Molecular Medicine (University of Oxford) Her work bridges cell physiology and translational medicine, with key discoveries on hypoxia-inducible factors (HIFs), iron regulatory genes TMPRSS6 and GDF15 , and the role of hepcidin in altitude adaptation and chronic diseases. She utilizes tissue-specific animal models to study iron regulation in heart, kidney, placenta, and vasculature. Recent publications highlight her contributions to understanding: FLASH radiotherapy effects linked to iron-dependent lipid peroxidation Clinical implications of myocardial iron dynamics in heart failure Hepcidin's role in vascular protection and placental iron transfer Biomarker development for predictive iron deficiency diagnostics Scientific Leadership: British Heart Foundation Intermediate Fellowship (2012) MRC Senior Fellowship (2020) BioIron Society Board Member (2019) She collaborates with clinical teams on translational projects and serves as a Tutorial Fellow in Medicine at Brasenose College, mentoring students in physiological sciences.

Ziad Mallatمشاهده پروفایل

استاد

• Cardiovascular biology
• immune mechanisms of cardiovascular disease
• atherosclerosis
• +۳ مورد دیگر

Professor Ziad Mallat is a distinguished Professor of Cardiovascular Medicine at the University of Cambridge, where he serves as the BHF Professor of Cardiovascular Medicine since 2010. He is affiliated with the Victor Phillip Dahdaleh Heart & Lung Research Institute and is a Principal Investigator in the Cardiovascular and Respiratory Medicine section of the Department of Medicine. Elected as a Fellow of the Academy of Medical Sciences (FMedSci) in 2020, Professor Mallat has established himself as a leading figure in cardiovascular immunology research. Professor Mallat received his MD and degree in Cardiovascular Disease from University of Paris VI, and his PhD from University of Paris VII. He was appointed Director of Research at Inserm, France, in 2007. His academic journey has positioned him at the forefront of cardiovascular research, with particular expertise in immune mechanisms of cardiovascular disease. Professor Mallat's research focuses on the immune mechanisms leading to cardiovascular inflammation in atherosclerosis, post-ischaemic injury (such as myocardial infarction), and aortic aneurysm and dissection. His laboratory develops novel immuno-modulatory and vaccination-based strategies to promote protective immune responses, aiming to radically change the management and treatment of these common and serious cardiovascular diseases. His approach combines basic science research, pre-clinical experimentation in animals, and translation clinical investigation in patients. Analysis of Professor Mallat's recent publications reveals a strong focus on the intersection of immunology and cardiovascular disease, particularly investigating regulatory T cells, B cell responses in atherosclerosis, and immune-modulatory therapies. His work spans from fundamental mechanisms to clinical translation, with several studies examining therapeutic approaches like low-dose interleukin-2 for cardiovascular inflammation. Fellow of the Academy of Medical Sciences (FMedSci) Co-Editor of Atherosclerosis journal Editorial Board member of Circulation Research and JCI Insight Professor Mallat has published over 250 papers in peer-reviewed journals, with landmark contributions including identifying prominent roles for specific pathogenic and regulatory immune pathways in atherosclerosis and post-ischaemic remodeling. His basic research activities are complemented by proof-of-concept clinical trials using immune-modulatory therapies in patients with coronary artery disease. He maintains active collaborations with the British Heart Foundation and is involved in the Cambridge BHF Centre of Research Excellence.

Devin Oglesbeeمشاهده پروفایل

استاد

• Molecular Genetics
• Biochemical Genetics
• Mitochondrial Diseases
• +۵ مورد دیگر

Dr. Devin Oglesbee is a Professor and current Chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic College of Medicine in Rochester, Minnesota. He serves as Clinical Competency Committee Chair for the Division of Laboratory Genetics and Genomics and maintains active roles in multiple professional organizations including the American College of Medical Genetics and Genomics. PhD in Molecular Biology from University of Oregon (2004) BS with Distinction from University of Oregon (1997) Post-Baccalaureate Program at Universite Lumiere, Lyon (1999) Residency and Fellowship training at Mayo Clinic in Clinical Molecular Genetics and Clinical Biochemical Genetics (2006-2007) Dr. Oglesbee's research focuses on molecular and biochemical genetics with particular emphasis on mitochondrial diseases, inborn errors of metabolism, and newborn screening methodologies. His work bridges laboratory medicine and clinical practice, developing innovative diagnostic approaches for rare genetic disorders. He has pioneered techniques in metabolomics, mass spectrometry-based diagnostics, and biomarker discovery for mitochondrial disorders. His publication record demonstrates consistent contributions to understanding genetic mechanisms of neurodevelopmental disorders, lysosomal storage diseases, and metabolic conditions. Recent work shows increasing focus on multi-omics integration, telehealth applications in rare disease diagnosis, and development of novel diagnostic methodologies for challenging genetic conditions. His research often involves collaboration through the Undiagnosed Diseases Network, highlighting his role in solving complex diagnostic cases. Excellence Through Teamwork Award from Mayo Clinic (2022) Multiple Travel Awards from Society of Inherited Metabolic Disease (2005-2006) William Sistrom Family Bioenergetics Scholarship from University of Oregon (2003) Molecular Biology Training Grant from National Institutes of Health (2000) As Department Chair, Dr. Oglesbee oversees laboratory operations while continuing active research in genetic diagnostics. His work has significantly influenced newborn screening protocols and diagnostic algorithms for metabolic disorders. He serves on numerous committees including the Clinical Laboratory Standards Institute Document Development Committee and as an Ad Hoc Reviewer for the College of American Pathologists, demonstrating leadership in establishing standards for laboratory medicine. Dr. Oglesbee is actively involved with the Mayo Clinic's Undiagnosed Diseases Network site, contributing to the diagnosis of rare genetic conditions through advanced genomic and metabolomic approaches. His laboratory focuses on developing and implementing novel diagnostic methodologies for mitochondrial disorders and inborn errors of metabolism, with particular expertise in mass spectrometry-based techniques.

Thomas Pulinilkunnilمشاهده پروفایل

استاد

• Metabolic Regulation
• Autophagy
• Lysosome Biology
• +۶ مورد دیگر

Dr. Thomas Pulinilkunnil is a Professor in the Department of Biochemistry and Molecular Biology at Dalhousie University, affiliated with Dalhousie Medicine New Brunswick. He joined the faculty in 2012. His research focuses on nutrient regulation of lysosomal metabolism, autophagy, and BCAA biology in cardiometabolic and cancer contexts. Education: PhD (University of British Columbia, 2005), Postdoctoral Fellowships at Harvard Medical School (2005-2008) and University of Alberta (2008-2012). Research Interests: Metabolic regulation of autophagy, lysosomal function in disease, BCAA metabolism in health and disease, ER glycosylation disorders, and cancer metabolism. His lab uses rodent, zebrafish, and yeast models to study these pathways. Publications: Over 60 peer-reviewed articles, with recent work on BCAA dysregulation in cardiometabolic disorders, TFEB's role in cancer cell survival, and lysosomal dysfunction in obesity-related heart failure. Key themes include nutrient-sensing pathways, mitochondrial-lysosome crosstalk, and translational applications in cancer therapy. Awards/Grants: Not explicitly listed, but his research is supported by grants from institutions like Dalhousie Medicine New Brunswick and collaborations with Saint John Regional Hospital. Labs/Teams: Leads the Pulinilkunnil Lab at Dalhousie, collaborating with teams like IMPART and CVRG. Current lab members include graduate students (e.g., Gurpreet Kaur, Max Merilovich) and postdocs (e.g., Sundaram Pakkirisami).

Teresa A. Zimmersمشاهده پروفایل

استاد

• Cancer Cachexia
• Pancreatic Cancer
• Muscle Wasting and Atrophy
• +۷ مورد دیگر

Teresa A. Zimmers is a Professor at Indiana University with extensive expertise in cancer cachexia, muscle wasting, and translational oncology. She holds a Ph.D. from The Johns Hopkins University School of Medicine (2001), a B.S. from Massachusetts Institute of Technology (1990), and completed postdoctoral training at the University of Rochester (2001-2003). Dr. Zimmers leads prominent academic initiatives as President of the Cancer Cachexia Society and co-organizer of international conferences including the 2023 Cancer Cachexia Conference and 2024 Keystone Conference. Her multidisciplinary research focuses on: Molecular mechanisms of cancer cachexia and muscle atrophy Sex-specific differences in cancer progression Pancreatic cancer pathophysiology Inflammatory signaling in organ injury Translational approaches for metabolic wasting disorders She maintains active memberships in the American Association for Cancer Research, Shock Society, and Society on Sarcopenia, Cachexia and Wasting Diseases. Honors recognizing her contributions include: Alliance of Distinguished and Titled Professors (Indiana University, 2019) Sigma Xi Honor Society (2019) Cancer Researcher of the Year (Women’s Cancer Association, 2009) Distinguished Investigator Award (University of Miami, 2005)

• Psychiatric Genetics
• Major Depressive Disorder
• Depression Subtypes
• +۳ مورد دیگر

Lu Yi is a Principal Researcher at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet. She leads the Precision Psychiatry research group and has directed the KI Psychiatric Genomics Institute since 2023. Her work bridges large-scale genomic data and electronic health records to advance precision psychiatry. Her research focuses on reducing heterogeneity in major depressive disorder (MDD) through genetic subtyping, with parallel interests in cardiometabolic comorbidities and trans-Nordic genomic collaborations. She employs genome-wide association studies (GWAS), polygenic risk scoring, and population register analyses to identify biological signatures of severe depression. Dr. Yi's publications emphasize genetic architecture of psychiatric disorders (e.g., MDD, schizophrenia), biomarker discovery, and real-world clinical applications. Recent works highlight depression subtypes, cross-disorder comorbidities, and brain-cell-type-specific pathways, reflecting a translational neuroscience approach. She received a €1.5 million European Research Council grant and leads Sweden's contributions to NIH/EU Horizon 2020 projects. Additional honors include co-chairing the 1,700+ member Psychiatric Genomics Consortium MDD working group. She advises PhD students (e.g., Ying Xiong, Arvid Harder) and postdoctoral researchers, focusing on genetic epidemiology and treatment-resistant depression. Her team collaborates internationally via the Nordic Tryggve consortium and KI-Psychiatric Genomics Institute infrastructure.

• Cancer Biology
• Biochemistry
• Cell Biology
• +۳ مورد دیگر

Sonia Lain is a Professor at Karolinska Institutet's Department of Microbiology, Tumor and Cell Biology. She leads the 'Discovery and Elucidation of the mechanisms of Action of Tumour Selective Compunds' research group, part of the Division of Tumor Biology. Her work focuses on identifying molecules with therapeutic potential for cancer, particularly targeting DHODH (dihydroorotate dehydrogenase) inhibitors and p53 pathway activation. She holds a Docent degree from Karolinska Institutet (2012) and has been a professor since 2015. Her research integrates biochemistry, cell biology, and molecular oncology to develop novel cancer therapies. Research interests include tumor-selective compounds, pyrimidine metabolism, and the p53 signaling pathway. Her group investigates how DHODH inhibitors disrupt cancer cell proliferation while sparing normal cells. Key projects involve modulating nucleotide imbalance in tumors and understanding mechanisms of drug resistance. Publications highlight advancements in DHODH inhibitor mechanisms, metabolic effects of these compounds, and p53 activation strategies. The lab's work has been featured in journals like Nature Communications and Cell Chemical Biology . Collaborations with institutions like KTH and the University of Oxford underscore interdisciplinary approaches to drug discovery. No specific grants or awards are listed, but her group's research is supported by donations. She advises on lab activities but no formal student names are provided. The lab's future work includes optimizing DHODH inhibitors for clinical translation and exploring combination therapies.

• Neuroendocrinology
• Metabolism
• Obesity Research
• +۵ مورد دیگر

Randy Seeley is the Henry King Ransom Endowed Professor of Surgery, Internal Medicine, and Nutritional Sciences at the University of Michigan School of Medicine. He directs the NIH-funded Michigan Nutrition Obesity Research Center (MNORC) and previously led the Cincinnati Diabetes and Obesity Center. His research focuses on the brain-gut axis in energy balance, GLP-1 agonists, and molecular mechanisms of bariatric surgery. Education: Ph.D. (University of Pennsylvania, 1993), B.A. (Grinnell College, 1989) Awards: Lilly Scientific Achievement Award (2003), Ernst Oppenheimer Award (2008), ADA Outstanding Scientific Achievement (2009) Collaborations: Over 390 peer-reviewed publications, industry partnerships with Novo Nordisk, Eli Lilly, and 48+ companies His recent work spans neuroendocrinology , metabolic surgery , and hormonal therapies for obesity/diabetes. Key trends include GLP-1 receptor agonists , gut-brain communication , and FGF15/19 pathways . He serves as Senior Associate Editor for Diabetes and chairs NIH review panels. Scientific Awards 2003 Lilly Scientific Achievement Award 2008 Ernst Oppenheimer Award 2009 ADA Outstanding Scientific Achievement Current grants include NIH projects on intestinal Reg3g, GFRAL expression, and collaborations with Bullfrog AI, Glyscend, and Eli Lilly. His lab explores molecular targets for obesity/diabetes, with media recognition in New York Times and Wall Street Journal .

Robert P. Doyleمشاهده پروفایل

استاد

• Medicinal Chemistry
• Drug Development
• Peptide Design and Synthesis
• +۳ مورد دیگر

Robert P. Doyle is the Jack and Laura H. Milton Professor and Dean’s Professor of Chemistry at Syracuse University, with affiliations in the College of Arts and Sciences. He holds a Ph.D. in Synthetic Chemistry from the University of Dublin (2001) and has expertise in medicinal chemistry, peptide design, and drug delivery. His research focuses on developing therapies for obesity, type 2 diabetes, and opioid use disorder, leveraging vitamin B12 conjugation and peptide engineering. Notable contributions include the creation of GLP-1 receptor agonists and multiagonist peptides that mitigate side effects like nausea. Doyle has authored over 80 publications, including recent work on chimeric peptides targeting obesity and opioid addiction. His grants include NIH-funded projects on metabolic syndrome treatments and GFRAL receptor antagonists. He teaches courses in medicinal chemistry, metals in medicine, and biochemical research. Awards include the Chancellor’s Citation for Excellence (2020) and endowed chairs recognizing his scholarly impact. His lab explores peptide stability, FRET-based assays, and the role of GDF15 in emesis. Collaborations with institutions like the University of Pennsylvania and industry partners (e.g., Coronation Bio, Inc.) highlight translational research efforts. Future work emphasizes multiagonist therapies and understanding central nervous system effects of gastrointestinal hormones.

• Genetic Epidemiology
• Women's Health
• Reproductive Health
• +۳ مورد دیگر

Marlena Fejzo, PhD, is a Clinical Assistant Professor of Population and Public Health Sciences at the University of Southern California (USC), working in the Center for Genetic Epidemiology. She also collaborates with Materna Biosciences, Inc. Her research focuses on women’s health, particularly conditions such as ovarian cancer, breast cancer, multiple sclerosis, uterine fibroids, and severe pregnancy complications like hyperemesis gravidarum (HG). Dr. Fejzo holds a PhD in Genetics from Harvard University (1995). She has published extensively on HG, identifying genetic risk factors such as GDF15 and IGFBP7. Her work challenges outdated theories of HG’s psychosomatic origins and advocates for evidence-based care. She serves as a science advisor and board member for the Hyperemesis Education and Research Foundation, advancing patient advocacy and clinical understanding. Education : PhD in Genetics, Harvard University, 1995 Research Interests : Dr. Fejzo’s work centers on genetic epidemiology of pregnancy-related conditions, particularly HG and its recurrence risk, neurodevelopmental impacts, and treatment efficacy. She employs GWAS, whole-exome sequencing, and clinical cohort studies to uncover genetic and environmental factors influencing disease severity and outcomes. Her studies emphasize translational research, aiming to improve diagnostic tools (e.g., the HELP Score) and therapeutic strategies for HG patients. Grants & Collaborations : Her research is supported by collaborations with institutions like Materna Biosciences and the Hyperemesis Education and Research Foundation. Key projects include investigating fetal-maternal GDF15 signaling and exploring cannabis use for HG symptom management. She has also validated clinical prediction models for HG severity. Labs/Teams : Affiliated with the Center for Genetic Epidemiology at USC, where she leads studies on genetic determinants of complex diseases, particularly in reproductive health contexts.

• Cancer Cell Motility
• Imaging Techniques
• Neoplasm
• +۷ مورد دیگر

Tony Ng is a Professor in Cell Imaging at the Comprehensive Cancer Centre, specializing in cancer cell motility and advanced imaging techniques. His work bridges biomedical research and clinical oncology, focusing on tumor mechanics, metastasis, and therapeutic response prediction. Research Interests : Cancer cell motility, fluorescence-lifetime imaging microscopy, tumor biomechanics, and neoplasm imaging. Projects : Lead investigator for RadNet Junior Group Leader and Co-Investigator for multi-scale mechanochemical signals research (MRC) and TNBC tissue state mapping (Wellcome Leap Inc.). Scientific Awards : Recipient of a competitive Fellowship (2003) and MRC Clinician Scientist (2000). Collaborations : Active in international conferences (e.g., International Society of Differentiation, FASEB) and peer-review panels (EPSRC, British Society for Cell Biology).

Marilena D'Aurelioمشاهده پروفایل

دانشیار

• Neuroscience
• Mitochondrial Diseases
• Metabolism
• +۳ مورد دیگر

Marilena D'Aurelio is an Associate Professor of Research in Neuroscience at the Brain and Mind Research Institute, Weill Cornell Medical College (Cornell University) since 2021. Her work bridges mitochondrial bioenergetics, metabolic disorders, and neurological disease mechanisms, with significant contributions to understanding cellular adaptations in mitochondrial pathologies. Her academic credentials include: B.S., M.S., University of Bologna (Italy), 1996 Ph.D., University of Bologna (Italy), 2001 Dr. D'Aurelio's research program centers on mitochondrial diseases , metabolic rewiring , and neurodegenerative mechanisms , employing advanced techniques like mass spectrometry imaging to map metabolic dysregulation. Her lab investigates how mitochondrial DNA mutations trigger compensatory metabolic pathways across organs, with recent work revealing how high-fat diets ameliorate cardiomyopathy in CHCHD10 models and how glutamine metabolism adapts in mutant cells. This translational approach identifies novel biomarkers and therapeutic targets for disorders like ALS and Barth syndrome. Analysis of her 15 most recent publications (2006-2025) shows consistent focus on mitochondrial bioenergetics across neurological, cardiac, and metabolic contexts. Key trends include the role of respiratory chain supercomplexes in disease thresholds, multi-organ metabolic compensation in human myopathies, and imaging-based discovery of metabolite ratios as diagnostic tools. Her work increasingly integrates dietary interventions and signaling pathways like GDF15-GFRAL for therapeutic development. Dr. D'Aurelio currently leads two major NIH-funded projects as Principal Investigator: "Targeting GDF15-GFRAL signaling in mitochondrial myopathies" (2025-2027) and "Metabolic remodeling of skeletal muscle in mitochondrial myopathies" (2020-2026), both from the National Institute of Arthritis & Musculoskeletal & Skin Diseases. These grants support mechanistic studies on metabolic adaptation and therapeutic targeting in mitochondrial disorders. She operates within the Brain and Mind Research Institute's collaborative ecosystem, where her team develops imaging technologies and metabolic assays to dissect disease mechanisms across neuronal, cardiac, and muscular tissues, with strong translational links to clinical neurology and metabolic medicine.

• Cancer Pharmacology
• Molecular Biology
• Tumor Suppressor p53
• +۵ مورد دیگر

Sonia Lain is a Professor of Molecular Cancer Pharmacology at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet in Stockholm, Sweden. She leads the "Discovery and Elucidation of the mechanisms of Action of Tumour Selective Compunds" research group, with part of her laboratory also located at Science for Life Laboratories in Stockholm. Her work focuses on developing novel cancer therapeutics through molecular pharmacology approaches targeting tumor suppressor mechanisms. Dr. Lain's educational and professional background includes: Doctoral studies in virology at the Centro de Biología Molecular de Madrid Postdoctoral work at the University of Gothenburg (Sweden) with an EMBO fellowship on oncoviruses Postdoctoral and group leader position at the University of Dundee (Scotland) where she reached Lecturer rank Docent at Karolinska Institutet (2012) Professor of Molecular Cancer Pharmacology at Karolinska Institutet (2015-present) Dr. Lain's primary research focuses on cancer pharmacology with special emphasis on tumor suppressor p53 and nucleotide metabolism. Her laboratory investigates how to activate p53 through various mechanisms, particularly by targeting dihydroorotate dehydrogenase (DHODH), an enzyme involved in pyrimidine ribonucleotide synthesis. Her groundbreaking work demonstrated that the tumor suppressor p53 can be activated by inhibiting its nuclear export, leading to the development of molecules that inhibit nuclear export for cancer treatment. Her team has discovered dozens of molecules that activate p53 through multiple molecular mechanisms, with current research focused on identifying and improving molecules that alter nucleotide synthesis for selective cancer therapy. Analysis of Dr. Lain's publication record reveals a strategic progression from fundamental molecular mechanisms to therapeutic applications. Her work shows how nucleotide metabolism, particularly pyrimidine synthesis through DHODH, can be exploited for cancer treatment. Recent research has expanded to include metabolic effects beyond direct cancer cell killing, such as impacts on glucose metabolism and immune function, demonstrating the complexity of targeting metabolic pathways in cancer. Her group has developed novel compounds like the HZ series that specifically target DHODH with promising therapeutic potential. Dr. Lain's research group includes several key members who contribute to the laboratory's work: Suhas Darekar - Senior Research Specialist Muhammad Mushtaq - Research Specialist The Lain laboratory operates within the Division of Tumor Biology at Karolinska Institutet, with facilities at both the main campus and Science for Life Laboratories. The group maintains extensive collaborations with other researchers at Karolinska Institutet and internationally, as evidenced by numerous co-authored publications. Their research integrates molecular biology, biochemistry, pharmacology, and cancer biology approaches to develop novel therapeutic strategies that selectively target cancer cells while preserving normal cell function, representing a promising direction in cancer treatment development.

• Prostate Cancer
• Oncology
• Lipid Metabolism
• +۳ مورد دیگر

Professor Lisa Horvath is a Medical Oncologist and faculty member at the Central Clinical School , University of Sydney. Her research focuses on prostate cancer with emphasis on lipid metabolism , biomarker discovery , and chemotherapy resistance . Research Interests: Lipidomic profiling in advanced prostate cancer Androgen receptor signaling pathways Germline genetic testing applications Neurotoxicity in cancer survivors Scientific Contributions: She has authored numerous high-impact publications on topics ranging from circulating lipid biomarkers to novel imaging agents in metastatic prostate cancer. Her work includes clinical trial protocols and cost-effectiveness analyses for precision oncology approaches. Current Role: Leads research on metabolic reprogramming in prostate cancer, collaborates with multidisciplinary teams on biomarker validation , and contributes to clinical guidelines development.

Hani Harbمشاهده پروفایل

استادیار

• Infectious Immunology
• Regulatory T-cell Biology
• Lung Inflammatory Diseases
• +۷ مورد دیگر

Hani Harb is a Junior Professor (W1) at the Institute for Medical Microbiology and Virology, Dresden University of Technology since 2022. His academic journey includes positions at Harvard Medical School as Instructor in Pediatrics/Junior Research Group Leader (2019-2020), Junior Research Group Leader at Justus-Liebig-University Giessen (2020-2021), and Medical Affairs Manager at AstraZeneca Germany (2021-2022). He completed his PhD in Immunology and Epigenetics at Philipps University Marburg under Prof. Harald Renz. Dr. Harb's research focuses on understanding molecular and cellular mechanisms of lung pathology, with particular emphasis on tolerance mechanisms and Regulatory T-cell function. His lab investigates how environmental factors like particulate matter affect immune responses through epigenetic modifications, and how microbiome components interact with the immune system in homeostasis and disease. His publication record shows a consistent focus on Treg cell biology, particularly the Notch4 signaling pathway in inflammatory lung diseases. His most cited works demonstrate how Notch4 in Regulatory T-cells governs lung inflammation in viral infections and asthma, establishing molecular switches between alveolar macrophages and Tregs that activate inflammatory responses. Identified Notch4 in Regulatory T-cells as key regulator in asthma and viral lung infections Discovered molecular switch (Jagged1-Notch4) mediating airway inflammation by ultrafine particles Established role of microbiota components in controlling human pathogens Investigated Treg cell mechanisms in post-COVID-19 syndrome Dr. Harb's lab employs advanced techniques including Chromatin Immunoprecipitation, flow cytometry, extracellular vesicle analysis, and mouse disease models. He currently supervises multiple PhD students and MD candidates working on projects related to lung immunology, microbiome interactions, and environmental impacts on immune responses. His research has significant implications for developing new therapies for inflammatory lung diseases and understanding long-term effects of environmental pollutants on immune function.